Hence, DLBCL patients with high PDE4B expression, contributing to their poorer prognosis, could be resistant to cAMP‐induced apoptosis associated with inhibition of the phosphatidylinositol 3‐kinase (PI3K)/AKT signaling pathway 34, 35. The gene discussed is PDE4B; the disease is diffuse large B-cell lymphoma.